Summit Therapeutics is trading higher as the market stays focused on the company’s approaching U.S. regulatory catalyst for ivonescimab, following FDA acceptance of its Biologics License Application with a Prescription Drug User Fee Act (PDUFA) goal date of November 14, 2026. Separately, the company has kept momentum in the narrative with multiple ivonescimab data sets featured around ELCC 2026 in advanced non-small cell lung cancer (NSCLC), reinforcing investor attention on efficacy details and potential labeling scope.

The key catalyst is the FDA review timeline for ivonescimab in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC in combination with chemotherapy, with the agency’s action date set for November 14, 2026. With the decision months away, incremental clinical read-throughs, conference visibility, and any regulatory updates can amplify day-to-day moves as positioning adjusts.

Investors will be watching for any FDA communications that change review timing, requests for additional information, or signals on potential advisory committee involvement. On the clinical side, continued disclosures from Phase III programs—particularly data relevant to difficult-to-treat subsets and outcomes like intracranial activity and quality-of-life—can influence expectations for adoption and peak sales if approval is granted.